Abacus Health Products, Inc. entered into a non-binding letter of intent to acquire World Wide Inc. on August 30, 2018. As of December 21, 2018, Abacus Health Products, Inc. entered into a definitive agreement to acquire World Wide Inc. As per the terms of agreement, Abacus subordinate voting shares to be issued upon the exchange of the subscription receipts will be exchanged for subordinate voting shares in the capital of the resulting issuer at an exchange ratio of one Abacus subordinate voting share for each one resulting issuer subordinate voting share. The compensation warrants will also be exchanged for compensation warrants of the resulting issuer, on substantially the same terms and conditions, on a one for one basis. World Wide Inc. will change its name to Abacus Health Products, Inc. or such other name as is directed by Abacus and acceptable to applicable regulatory authorities effective upon closing. Pursuant to the transaction, World Wide will apply to list on the Canadian Securities Exchange. As of December 21, 2018, Abacus completed an offering of 3.272 million subscription receipts for a gross proceed of CAD 16.55 million. Upon closing of the transaction, all of World Wide's current directors and executive officers will resign and the Board of Directors of the Resulting Issuer will, subject to the approval of governing regulatory bodies, consist of between 3 and 7 directors, each of which shall be appointed by Abacus in its sole discretion. All of the executive officers shall be replaced by nominees of Abacus, all in a manner that complies with the requirements of governing regulatory bodies and applicable securities and corporate laws. The Board of Directors of the resulting issuer expected to includes the following Phillip Henderson as Director, Jesse Kaplan as Director, Eval Rosenthal as Director, Perry Antelman as Chairman of the Board of Directors and Chief Executive Officer, Henry R Hague as Chief Financial Officer. The transaction is subject to the execution of a definitive agreement, completion of mutually satisfactory due diligence, completion of the World Wide Meeting Matters and receipt of all required regulatory, corporate and third party approvals, including approvals by governing regulatory bodies, the shareholders of World Wide, the shareholders of Abacus, Aidance Skincare, parent of Abacus shareholders approval, applicable governmental authorities, and the fulfillment of all applicable regulatory requirements and conditions necessary to complete the transaction. The closing of the transaction is expected to occur by mid-January 2019. Eric Levy of Osler, Hoskin & Harcourt LLP acted as legal advisor to Abacus Health. Shimmy Posen of Garfinkle, Biderman LLP acted as legal advisor to World Wide. Abacus Health Products, Inc. (CNSX:ABCS) completed the acquisition of World Wide Inc. on January 29, 2019.